Fresenius SE KGaA (XTER:FRE) Interest Received


XTER:FRE Fresenius SE & Co KGaA XTER:FRE
66 GF Score
Price €42.12
GF Value €36.57
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

XTER:FRE
66GF Score
Fresenius SE & Co KGaA XTER:FRE
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fresenius SE KGaA (XTER:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of €42.12 is trading 15.2% above its estimated GF Value™ of €36.57. GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.

Key valuation signals for XTER:FRE:

  • Interest Received:
  • GF Value™: €36.57 vs. price of €42.12 (15.2% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XTER:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
66GF Score

Get the complete analysis for XTER:FRE

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.12
Price
€36.57
GF Value